The Challenges of Handling Neovascular Glaucoma at Undaan Eye Hospital Surabaya, Indonesia
Downloads
Introduction: Neovascular glaucoma (NVG) is a secondary glaucoma, frequently incurable, and can cause blindness. It is characterized by neovascularization over the iris, IOP elevation, and glaucomatous optic neuropathy. Retinal ischemia, which supplies the release of angiogenesis factors, is the leading factor of NVG. Anti-vascular endothelial growth factor (Anti-VEGF) agents are effective at iris and iridocorneal angle neovascularization. Furthermore, laser and surgery are still necessary to decrease intraocular pressure in the condition with ineffective medication. Delay in treatment can lead to sight-threatening glaucoma. Purpose: This study aimed to provide an overview of the incidence and management of NVG at Undaan Eye Hospital, Surabaya, Indonesia. Methods: This descriptive epidemiology study comprised 111 eyes of 102 patients. The inclusion criteria were patients diagnosed with NVG who came to Undaan Eye Hospital for one year (January 2021 to December 2021). Patients with incomplete medical records were excluded. The patient's age, gender, risk factors, and treatment were reviewed. Results: There were 102 patients (111 eyes) diagnosed with NVG. The patients were primarily men (53.2%), and the mean age was 54.98 ± 12.4 years. Diabetes mellitus (DM) was observed in 70 (63.1%) eyes, hypertension in 60 (54.1%) eyes, central retinal vein occlusion (CRVO) in 11 (9.9%) eyes, cholesterol in seven (6.3%) eyes, and branch retinal vein occlusion (BRVO) in one (0,9%) eye. The mean IOP at the time of diagnosis was 42.8 ± 11.2 mmHg. Anti-VEGF (25.2%), trabeculectomy (59.5%), glaucoma drainage device (17.1%), micropulse transscleral cyclophotocoagulation (5.4%) were done as an option of the treatment. Conclusions: NVG is more common in men. Most patients presenting NVG had DM and hypertension with a mean IOP of 42.8 mmHg. Trabeculectomy is the most commonly performed procedure.
Senthil S, Dada T, Das T, Kaushik S, Puthuran G, Philip R, et al. Neovascular glaucoma - A review. Indian J Ophthalmol 2021;69:525. https://doi.org/10.4103/ijo.IJO_1591_20.
SooHoo JR, Seibold LK, Pantcheva MB, Kahook MY. Aflibercept for the treatment of neovascular glaucoma. Clin Exp Ophthalmol 2015;43:803–807. https://doi.org/10.1111/ceo.12559.
Li Z, Zhou M, Wang W, Huang W, Chen S, Li X, et al. A prospective comparative study on neovascular glaucoma and non-neovascular refractory glaucoma following Ahmed glaucoma valve implantation. Chin Med J (Engl) 2014;127:1417–1422.
Herdiawan MA. Karakteristik Klinis Glaukoma Neovaskular pada Penderita Retinopati Diabetik di Pusat Mata Nasional Rumah Sakit Mata Cicendo. Observational Research. Fakultas Kedokteran Universitas Padjadjaran, Pusat Mata Nasional Rumah Sakit Mata Cicendo, 2016.
Mannina A, Olivier M, Patrianakos T. Neovascular glaucoma. Disease-a-Month 2021;67:101137. https://doi.org/10.1016/j.disamonth.2021.101137.
Medert CM, Sun CQ, Vanner E, Parrish RK, Wellik SR. The influence of etiology on surgical outcomes in neovascular glaucoma. BMC Ophthalmol 2021;21:440. https://doi.org/10.1186/s12886-021-02212-x.
Dumbraveanu L, Cusnir V, Bobescu D. A review of neovascular glaucoma. Etiopathogenesis and treatment. Rom J Ophthalmol 2021;65:315–329. https://doi.org/10.22336/rjo.2021.66.
Barac IR, Pop MD, Gheorghe AI, Taban C. Neovascular secondary glaucoma, etiology and pathogenesis. Rom J Ophthalmol 2015;59:24–28.
Mishra C, Meyer JJ. Neovascular Glaucoma. 2023. StatPearls [Internet]. https://www.ncbi.nlm.nih.gov/books/NBK576393 (accessed September 25, 2023).
SooHoo JR, Seibold LK, Kahook MY. Recent Advances in the Management of Neovascular Glaucoma. Semin Ophthalmol 2013;28:165–172. https://doi.org/10.3109/08820538.2012.730103.
Shalim NM. Karakteristik Klinis dan Tatalaksana Glaukoma Neovaskular pada Retinopati Diabetik di PMN RS Mata Cicendo. Observational Research. Fakultas Kedokteran Universitas Padjadjaran, Pusat Mata Nasional Rumah Sakit Mata Cicendo, 2019.
Indrahadi D, Wardana A, Pierewan AC. The prevalence of diabetes mellitus and relationship with socioeconomic status in the Indonesian population. Jurnal Gizi Klinik Indonesia 2021;17:103. https://doi.org/10.22146/ijcn.55003.
Rodrigues GB, Abe RY, Zangalli C, Sodre SL, Donini FA, Costa DC, et al. Neovascular glaucoma: A review. Int J Retina Vitreous 2016;2:26. https://doi.org/10.1186/s40942-016-0051-x.
Yang H, Yu X, Sun X. Neovascular glaucoma: Handling in the future. Taiwan J Ophthalmol 2018;8:60–66. https://doi.org/10.4103/tjo.tjo_39_18.
Rong AJ, Swaminathan SS, Vanner EA, Parrish RK. Predictors of neovascular glaucoma in central retinal vein occlusion. Am J Ophthalmol 2019;204:62–69. https://doi.org/10.1016/j.ajo.2019.02.038.
Liao N, Li C, Jiang H, Fang A, Zhou S, Wang Q. Neovascular glaucoma: A retrospective review from a tertiary center in China. BMC Ophthalmol 2016;16:14. https://doi.org/10.1186/s12886-016-0190-8.
Olmos LC, Sayed MS, Moraczewski AL, Gedde SJ, Rosenfeld PJ, Shi W, et al. Long-term outcomes of neovascular glaucoma treated with and without intravitreal bevacizumab. Eye (Lond) 2016;30:463–472. https://doi.org/10.1038/eye.2015.259.
Nakatake S, Yoshida S, Nakao S, Arita R, Yasuda M, Kita T, et al. Hyphema is a risk factor for failure of trabeculectomy in neovascular glaucoma: A retrospective analysis. BMC Ophthalmol 2014;14:55. https://doi.org/10.1186/1471-2415-14-55.
Simha A, Aziz K, Braganza A, Abraham L, Samuel P, Lindsley KB. Anti-vascular endothelial growth factor for neovascular glaucoma. Cochrane Database of Systematic Reviews 2020;2020. https://doi.org/10.1002/14651858.CD007920.pub3.
Xie Z, Liu H, Du M, Zhu M, Tighe S, Chen X, et al. Efficacy of ahmed glaucoma valve implantation on neovascular glaucoma. Int J Med Sci 2019;16:1371–1376. https://doi.org/10.7150/ijms.35267.
Iwasaki K, Kojima S, Wajima R, Okazaki T, Yokoyama Y, Inoue T, et al. Comparing surgical outcomes in neovascular glaucoma between tube and trabeculectomy: A multicenter study. Ophthalmol Glaucoma 2022;5:672–680. https://doi.org/10.1016/j.ogla.2022.05.003.
Copyright (c) 2023 Rosalia Adriani Malika, Lydia Nuradianti
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Vision Science and Eye Health Journal by Universitas Airlangga is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
The journal allows the author to hold the copyright of the article without restrictions.
The journal allows the author(s) to retain publishing rights without restrictions.
The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution-Share-Alike (CC BY-SA).
The Creative Commons Attribution-Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violations.
